Roche
4300 Hacienda Drive
Pleasanton
California
94588
United States
Tel: 925-730-8000
Fax: 925-225-0479
Website: http://molecular.roche.com/
About Roche
Roche Molecular Solutions, one of the global business areas within Roche Diagnostics, brings together the diagnostic power of molecular, tissue and sequencing technologies.
With the goal of revolutionizing diagnostic decisions through integrated solutions, Roche Molecular Solutions brings together the latest technologies withinmolecular diagnostics (polymerase chain reaction or PCR-based testing), tissue diagnostics (tissue biopsy testing) and sequencing solutions (next-generation DNA and RNA sequence-based testing) to advance the standard of care for everyone.
Roche is the world leader in molecular and tissue diagnostics, and one of the leaders in clinical sequencing. As the innovation engine for Roche Diagnostics,Roche Molecular Solutions is translating cutting-edge science and innovation into clinical practice.
Visit our Career Blogs to see what our employees have to say about their life at Roche!
https://molecular.roche.com/
https://sequencing.roche.com
http://www.ventana.com/
101 articles about Roche
-
Alexandria Real Estate Equities, an urban office real estate investment company specializing in the life sciences, is expanding its Alexandria LaunchLabs into the East Cambridge, Massachusetts area.
-
Roche announced it had temporarily halted recruiting patients to its Phase II MODUL clinical trial for metastatic colorectal cancer after four patient deaths. The patients were receiving Tecentriq (atezolizumab) in combination with Exelixis’ MEK inhibitor Cotellic (cobimetinib).
-
Swiss pharma giant Roche has had an active April so far. The company has acquired a multiple sclerosis program, completed the acquisition of a company and secured a big win with the United Kingdom’s healthcare provider for lung cancer drug Tecentriq.
-
Novartis has struck a deal to acquire AveXis for $8.7 billion. Novartis will pay $218 per share, which is a 72 percent premium over AveXis’s 30-day volume-weighted average stock price.
-
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
-
Eli Lilly and Company announced top-line data from its Phase III REACH-2 trial of Cyramza (ramucirumab) as a monotherapy second-line treatment for hepatocellular carcinoma (HCC), which is liver cancer.
-
Building on a four-year-old relationship Roche struck a deal to acquire a regenerative therapy program for multiple sclerosis from Inception Sciences, a drug discovery engine co-founded with Versant Ventures in 2011.
-
Inception Neuroscience Program Acquired by Roche
4/4/2018
Another successful outcome from a Versant Discovery Engine Launching successor company, Pipeline Therapeutics
-
The Hemophilia Federation of America and the National Hemophilia Foundation announced that they had been contacted by Genentech, a Roche company, about the deaths of five patients receiving Hemlibra (emicizumab-kxwh) for hemophilia A.
-
Roche launches VENTANA DP 200 slide scanner for digital pathology
3/26/2018
- Image quality and ease of use set new standard for digital pathology, with the goal of empowering faster, better care for patients - Able to produce high-quality images from a wide variety of histology samples, special stains, bone marrow and cytology and frozen tissue sections
-
Novartis released full results from its Phase III EXPAND trial of siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS), which it published in the journal The Lancet.
-
Regeneron Pharmaceuticals announced positive topline data from its Phase III PANORAMA clinical trial of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.
-
Roche's John Reed Is Stepping Down
3/8/2018
John Reed, who for five years has led Roche’s Pharma Research and Early Development (pRED) research group, is stepping down for personal reasons. -
Late Thursday the companies touted biomarker data from an early-stage study that showed the drug lowered the disease-causing protein in people with the disease.
-
Roche achieves two major milestones in the evolution of decision support platform
3/2/2018
-- HITRUST CSF® certification granted for NAVIFY™ Tumor Board solution -- Belmont site received ISO/IEC 27001 certification -- Commitment to Patient Data Safety and Cybersecurity
-
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
-
Emulate, Inc. Announces Strategic Partnership with Roche to Apply the ‘Human Emulation System’ as a Platform for Drug Discovery
2/20/2018
Scientists from Emulate and Roche form innovative partnership to use Organ-Chips for testing of efficacy and safety of new antibody therapeutics and combination therapies
-
The U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Imfinzi to treat patients with unresectable Stage III non-small cell lung cancer (NSCLC).
-
Despite the recent dismal news regarding Alzheimer’s drug development, the U.S. Food and Drug Administration (FDA) recently proposed new guidelines for developing drugs for the disease.
-
Roche will plunk down $1.9M to acquire Flatiron Health, which has previously been backed by GV, as well as Roche.